TLX — Telix Pharmaceuticals Limited stock price, charts and financials
QT64Telix Pharmaceuticals LimitedTelix Pharmaceuticals Limited (NASDAQ: TLX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 125.10 | EPS (ttm) | 0.10 | Insider Own | 6.13% | Shs Outstand | 338.78M | Perf Week | 5.13% |
| Market Cap | 4.24B | Forward P/E | - | EPS next Y | 0.02 | Insider Trans | 0.34% | Shs Float | 272.81M | Perf Month | 5.30% |
| Enterprise Value | 4.56B | PEG | 1.59 | EPS next Q | - | Inst Own | - | Short Float | 0.10% | Perf Quarter | 25.86% |
| Income | 34.00M | P/S | 4.72 | EPS this Y | -20.68% | Inst Trans | - | Short Ratio | 1.62 | Perf Half Y | 48.75% |
| Sales | 897.00M | P/B | 8.76 | EPS next Y | -80.81% | ROA | 2.40% | Short Interest | 264.94K | Perf YTD | 67.02% |
| Book/sh | 1.43 | P/C | 16.95 | EPS next 5Y | 78.84% | ROE | 7.11% | 52W High | 13.11 -4.58% | Perf Year | 32.80% |
| Cash/sh | 0.74 | P/FCF | - | EPS past 3/5Y | - | ROIC | -0.58% | 52W Low | 6.28 99.20% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 147.20 | Sales past 3/5Y | 91.38% 186.94% | Gross Margin | 52.16% | Volatility | 4.29% 2.67% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 5.09 | EPS Y/Y TTM | 8.28% | Oper. Margin | -0.73% | ATR (14) | 0.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | Sales Y/Y TTM | 73.50% | Profit Margin | 3.60% | RSI (14) | 57.16 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.01 | EPS Q/Q | 81.27% | SMA20 | 6.72% | Beta | 1.07 | Target Price | 18.00 |
| Payout | 0.00% | Debt/Eq | 1.11 | Sales Q/Q | 292.00% | SMA50 | 11.07% | Rel Volume | 2.13 | Prev Close | 11.83 |
| Employees | 1,152 | LT Debt/Eq | 1.08 | Earnings | Feb 19 | SMA200 | 30.98% | Avg Volume | 193.82K | Price | 12.51 |
| IPO Date | Nov 14, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 85.66% 25507.52% | Net Debt/EBITDA | 10.48 | Volume | 412,902 | Change | 5.75% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-16-26 | Reiterated | RBC Capital | $17 → $18 | |
| Dec-15-25 | Initiated | RBC Capital | Sector Perform | $17 |
| Sep-23-25 | Reiterated | UBS | Buy | $20 |
| Sep-10-25 | Reiterated | HC Wainwright & Co. | Buy | $20 |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 897 | 778 | 517 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 429 | 365 | 180 | — | — | — | — | — | — | |
| Gross Profit | 468 | 413 | 336 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 260 | 230 | 137 | — | — | — | — | — | — | |
| Research and Development | 215 | 166 | 80 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 65 | — | — | — | — | — | — | |
| Operating Income | -8 | 17 | 54 | — | — | — | — | — | — | |
| Interest Expense | 13 | 36 | 14 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 50 | 13 | -3 | — | — | — | — | — | — | |
| Net Income Before Taxes | 30 | -5 | 37 | — | — | — | — | — | — | |
| Income Taxes | -5 | 2 | 4 | — | — | — | — | — | — | |
| Consolidated Net Income | 34 | -7 | 33 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 34 | -7 | 33 | — | — | — | — | — | — | |
| Net Income | 34 | -7 | 33 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.10 | -0.02 | 0.10 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.10 | -0.02 | 0.10 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.10 | -0.02 | 0.09 | — | — | — | — | — | — | |
| EBITDA | 31 | 52 | 65 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 125.10 | — | 166.75 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.73 | 3.25 | 9.86 | — | — | — | — | — | — | |
| Gross Margin | 52.17 | 53.08 | 64.99 | — | — | — | — | — | — | |
| Operating Margin | -0.89 | 2.19 | 10.44 | — | — | — | — | — | — | |
| Net Margin | 3.79 | -0.90 | 6.38 | — | — | — | — | — | — | |
| Shares Outstanding | 339 | 338 | 331 | — | — | — | — | — | — | |
| Market Capitalization | 4,241 | 2,532 | 5,097 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Smith Darren Charlton | Group Chief Financial Officer | Sep 07 '26 | Buy | 9.66 | 2,071 | 19,998 | 13,992 | Sep 14 |
| Behrenbruch Christian | MD & Group CEO | Apr 29 '26 | Buy | 14.87 | 33,435 | 497,178 | 20,742,935 | May 06 |
| Behrenbruch Christian | MD & Group CEO | Apr 28 '26 | Buy | 14.48 | 34,500 | 499,560 | 20,709,500 | May 06 |
| Smith Darren Charlton | Group Chief Financial Officer | Mar 29 '26 | Option Exercise | 0.00 | 1,111 | 0 | 11,921 | Apr 01 |
| BRANDT RICHARD PAUL | director, 10 percent owner: | Sep 11 '07 | Option Exercise | 4.03 | 2,500 | 10,063 | 5,160 | Sep 14 |